Abstract：Objective To investigate the clinical effect of dexamethasone on chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods Eighty patients with advanced NSCLC admitted into our hospital from January to December in 2016 were enrolled and randomly divided into two groups.40 cases of the control group was used with chemothrapy,while 40 cases of the research group was added with dexamethasone.The therapeutic effect was compared in both groups.Results There was no statistically significant difference in short-term effective rate between the two groups(P＞0.05).Before therapy,the levels of HIF-1α and VEGF had no statistically significant difference (P＞0.05).After treatment,they were both improved,and the levels in the research group were much lower compared with those in the control group (P＜0.05).Before treatment,the immune function in the two groups had no statistically significant difference(P＞0.05).After treatment,they were both improved,and improvement in the research group was superior to that in the control group (P＜0.05).Conclusion For patients with advanced NSCLC,combination of dexamethasone is beneficial to improve patients′immune function,which should be recommended for clinical application.
Checinsk a A，Hoogeland BSJ，Rodriguez JA，et al.Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells[J].ECR，2016，313 （6）：1215-1224.
Schuler M，Yang JC，Park K，et al.Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy，erlotinib/gefitinib and afatinib：phase Ⅲ randomized LUX-Lung 5 trial.[J].AOO，2016，27（3）：417-423.
Kazandjian D，Suzman DL，Blumenthal G，et al.FDA approval summary：Nivolumab for the treatment of metastatic nonsmall cell lung cancer with progression on or after platinum-based chemotherapy[J].Oncologist，2016，21（5）：634-642.
京公网安备 11010502046607号